Our results of αPTX3i safety, therapeutic efficiency in pulmonary fibrosis and compared with pirfenidone and nintedanib support that targeting PTX3 may be an effective strategy for lung injury‐induced fibrosis. Here, PTX3 is linked to fibrosis.